Retrospective Study
Copyright ©The Author(s) 2024.
World J Gastrointest Surg. Jan 27, 2024; 16(1): 85-94
Published online Jan 27, 2024. doi: 10.4240/wjgs.v16.i1.85
Table 1 Comparison of clinical data between the two groups
Clinical dataTraining set
t/Z/χ2P valueValidation set
t/Z/χ2P value
No lymph node metastasis (n = 141)
Lymph node metastasis (n = 228)
No lymph node metastasis (n = 51)
Lymph node metastasis (n = 72)
Gender1.0170.3131.1260.289
Male99 (70.2)171 (75.0)33 (64.7)53 (73.6)
Female42 (29.8)57 (25.0)018 (35.3)19 (26.4)
Age (yr)0.0150.9014.7290.030
≤ 6064 (45.4)105 (46.1)27 (52.9)24 (33.3)
> 6077 (54.6)123 (53.9)24 (47.1)48 (66.7)
Mode of operation7.8160.0053.5780.059
Partial gastrectomy113 (80.1)152 (66.7)43 (84.3)50 (69.4)
Total gastrectomy28 (19.9)76 (33.3)8 (15.7)22 (30.6)
Tumor invasion depth-11.022< 0.001-7.114< 0.001
T161 (43.3)13 (5.7)30 (58.8)4 (5.6)
T242 (29.8)22 (9.6)13 (25.5)13 (18.1)
T321 (14.9)64 (28.1)6 (11.8)27 (37.5)
T417 (12.1)129 (56.6)2 (3.9)28 (38.9)
Tumor site0.7160.6990.3920.822
Gastric body24 (17.0)32 (14.0)18 (35.3)22 (30.6)
Gastric antrum73 (51.8)126 (55.3)26 (51.0)38 (52.8)
Gastric cardia44 (31.2)70 (30.7)7 (13.7)12 (16.7)
Nerve or vascular invasion128.649< 0.00154.772< 0.001
No108 (76.6)39 (17.1)42 (82.4)11 (15.3)
Yes33 (23.4)189 (82.9)9 (17.6)61 (84.7)
Maximum tumor diameter38.634< 0.0018.3230.004
≤ 5 cm122 (86.5)126 (55.3)46 (90.2)49 (68.1)
> 5 cm19 (13.5)102 (44.7)5 (9.8)23 (31.9)
PIV132.00 (80.73, 226.80)190.72 (106.49, 311.44)-3.606< 0.001149.43 (91.73, 217.49)173.59 (102.20, 274.73)-1.5860.113
CEA2.47 (1.53, 3.58)2.90 (1.82, 6.87)-3.1890.0012.65 (1.47, 3.95)4.91 (1.97, 9.02)-2.3310.020
Table 2 Prediction performance evaluation of each model
Model
AUC
Accuracy
Kappa
Sensitivity (recall rates)
Specificity
DT0.8240.8210.6380.8060.843
RF0.9230.8540.7020.8470.882
SVM0.7210.5850.0000.7500.547
GBM0.9270.8700.7340.8750.863
NB0.9140.8210.6400.8610.843
MLP0.9070.8370.6650.8820.824
LR0.8980.8210.6360.8060.882